Ad-hoc | 18 May 2021 12:46
|
Aladdin Healthcare Technologies SE / Key word(s): Disposal
Aladdin Healthcare Technologies SE
reports the sale of software and intellectual property
Aladdin Ltd has developed and is developing various AI-driven technology products for the healthcare market. It has developed prototype AI-driven Drug Discovery Platform and Knowledge Graph which can be tailored to various areas of drug development. The software being sold is the above-described intellectual property but specifically to be used for small molecule drug discovery in the area of Alzheimer’s and Dementia. Aladdin retains the rights to use it in other areas. Wade Menpes-Smith
Contact:
18-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|
| Language: | English |
| Company: | Aladdin Healthcare Technologies SE |
| Unter den Linden 10 | |
| 10117 Berlin | |
| Germany | |
| Phone: | 030 700140449 |
| E-mail: | info@aladdinid.com |
| Internet: | www.aladdinid.com |
| ISIN: | DE000A12ULL2 |
| WKN: | A12ULL |
| Listed: | Regulated Market in Dusseldorf |
| EQS News ID: | 1197804 |
| End of Announcement | DGAP News Service |